JB+A is excited to share good news involving its client partner, PKD Foundation. PKD, a chronic, genetic disease, is characterized by uncontrolled growth of cysts in the kidneys and other organs and can lead to kidney failure. Previously, there had been no treatment specifically for PKD in the U.S., with the only option for survival a transplant or dialysis. Today, there is new hope.

U.S. Food and Drug Administration (FDA) granted approval of JYNARQUE™ (tolvaptan) to be the first treatment in the U.S for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease (PKD). The PKD Foundation not only supported early studies that led to the development of JYNARQUE™ as a treatment, but also helped guide PKD patients to the JYNARQUE™ clinical trials.

Although not a cure, patients who are prescribed JYNARQUE™ for PKD will see a slower decline in their kidney function, leading to improved health and well-being. “Today is an historic day in providing hope to patients with polycystic kidney disease, and we are thrilled to be a part of this first milestone to treat patients with ADPKD,” said Andy Betts, CEO of the PKD Foundation. “For the past 35 years, our goal has been to support PKD patients from care to cure. It is gratifying to play a part in the discovery of this treatment and to see it come to fruition.”

Betts also recognizes all of the patients who graciously took the time and resources to participate in the clinical trials to bring JYNARQUE™ to the PKD community: “This treatment would not exist without these patients,” says Betts. “We hope that this is just the beginning of new treatments on the horizon for patients suffering from PKD. We will continue to stand beside PKD patients until there is a cure, supporting them with access to future studies, to new treatments, and to ensure the affordability of care.”

JB+A is proud of PKD Foundation for this milestone achievement, and for the unwavering care and support it provides to those living with PKD.

About PKD Foundation:
PKD Foundation has been dedicated since its founding in 1982 to supporting and improving the lives of patients affected by polycystic kidney disease. These efforts are accomplished through promoting research to find treatments and a cure, as well as providing education, advocacy and awareness on a national level. The Foundation provides direct services to local communities nationwide and is the largest private funder of PKD research.

PKD Foundation is the only organization in the United States solely dedicated to finding treatments and a cure for PKD. Our mission: We give hope. We fund research, advocate for patients and build a community for all affected by polycystic kidney disease (PKD).

To learn more about PKD Foundation, visit here.

To learn more about JYNARQUE™, visit here.